Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacokinetic Modelling to Predict FVIII:C Response to Desmopressin and Its Reproducibility in Nonsevere Haemophilia A Patients.

Thrombosis and haemostasis - 1 Apr 2018

Schütte Lisette M, van Hest Reinier M, Stoof Sara C M, Leebeek Frank W G, Cnossen Marjon H, Kruip Marieke J H A, Mathôt Ron A A

Abstract excerpt

BACKGROUND: Nonsevere haemophilia A (HA) patients can be treated with desmopressin. Response of factor VIII activity (FVIII:C) differs between patients and is difficult to predict. OBJECTIVES: Our aims were to describe FVIII:C response after desmopressin and its reproducibility by population pharmacokinetic (PK) modelling. PATIENTS AND METHODS: Retrospective data of 128 nonsevere HA patients (age 7-75 years)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Coagulation Tests
Share to Deamino Arginine Vasopressin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Factor VIII

Share to Hemophilia A

Share to Hemorrhage

Share to Nonlinear Dynamics

Share to Reproducibility of Results

Share to Young Adult

Source

Identifiers

PMID: 29458233
DOI: 10.1160/TH17-06-0390

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacokinetic Modelling to Predict FVIII:C Response to Desmopressin and Its Reproducibility in Nonsevere Haemophilia A Patients.PMID 29458233Read ↗

Genotype-Dependent Response to Desmopressin in Hemophilia A and Proposal of a Predictive Response Score.Semantic proximity Read ↗

Desmopressin in moderate hemophilia A patients: a treatment worth considering.Semantic proximity Read ↗

Molecular and phenotypic determinants of the response to desmopressin in adult patients with mild hemophilia A.Semantic proximity Read ↗

Variable pharmacokinetics of coagulation factor VIII in the perioperative setting complicates personalisation of treatment in patients with haemophilia ASemantic proximity Read ↗

von Willebrand factor and factor VIII levels after desmopressin are associated with bleeding phenotype in type 1 VWD.Semantic proximity Read ↗

Correlation between FIX genotype and pharmacokinetics of Nonacog alpha according to a multicentre Italian study.Semantic proximity Read ↗

Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD.Semantic proximity Read ↗

Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX.Semantic proximity Read ↗

Response to desmopressin is strongly dependent on F8 gene mutation type in mild and moderate haemophilia A.Semantic proximity Read ↗

Biological effect of desmopressin in eight patients with type 2N ('Normandy') von Willebrand disease. Collaborative Group.Semantic proximity Read ↗

Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study.Semantic proximity Read ↗

Factor VIII:C increases after desmopressin in a subgroup of patients with autosomal recessive severe von Willebrand disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.